Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from HeraMED Ltd. ( (AU:HMD) ).
HeraMED Limited, a digital health company specialising in remote maternity care, develops and markets the HeraCARE platform, which combines hardware, software, and data analytics to deliver integrated, cost-efficient prenatal and postpartum monitoring. Its solution is designed to keep expectant mothers engaged and supported while enabling clinicians to detect and prevent potential risks earlier.
The company has scheduled its Annual General Meeting for 21 May 2026 in Hawthorn East, Victoria, and has distributed the notice of meeting, letter to shareholders, and proxy form in line with ASX requirements. The AGM will provide shareholders with an opportunity to engage with the board and management as HeraMED advances its digital maternity care platform and seeks to strengthen its position in the evolving telehealth and maternal health markets.
More about HeraMED Ltd.
HeraMED Limited is an Australian digital health and medical technology company focused on transforming maternity care through its hybrid remote pregnancy monitoring and digital engagement platform, HeraCARE. The company’s proprietary ecosystem integrates its clinically validated in-home fetal and maternal heart rate monitor HeraBEAT with cloud computing, artificial intelligence, and big data to enhance prenatal and postpartum care for expectant mothers and healthcare providers.
YTD Price Performance: 27.78%
Average Trading Volume: 1,011,785
Technical Sentiment Signal: Buy
Current Market Cap: A$53.13M
For an in-depth examination of HMD stock, go to TipRanks’ Overview page.